The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.

Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.

Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.

Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.

Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.

Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Eroltinib for early-stage lung cancer.

Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.